Crinetics Pharmaceuticals (CRNX) Financials

$36.78 -0.02 (-0.05%)

As of 04:00 PM Eastern

Annual Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298	-465
Consolidated Net Income / (Loss)	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298	-465
Net Income / (Loss) Continuing Operations	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298	-465
Total Pre-Tax Income	-6.02	-9.16	-27	-50	-74	-108	-164	-209	-298	-465
Total Operating Income	-6.04	-9.13	-29	-54	-75	-108	-168	-223	-339	-517
Total Gross Profit	0.59	2.05	2.43	1.19	0.14	1.08	4.74	4.01	1.04	6.62
Total Revenue	0.59	2.05	2.43	1.19	0.14	1.08	4.74	4.01	1.04	7.70
Operating Revenue	0.59	2.05	2.43	1.19	0.14	1.08	4.74	4.01	1.04	7.70
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.08
Operating Cost of Revenue	-	-	-	-	-	-	-	0.00	0.00	1.08
Total Operating Expenses	6.63	11	31	55	75	109	173	227	340	523
Selling, General & Admin Expense	1.53	1.94	6.66	14	18	25	42	58	100	191
Research & Development Expense	5.10	9.23	24	42	57	84	130	169	240	332
Total Other Income / (Expense), net	0.03	-0.03	1.60	3.41	0.99	0.16	3.96	13	41	52
Interest & Investment Income	0.04	0.03	1.75	3.46	0.99	0.16	3.31	13	41	52
Other Income / (Expense), net	-0.00	-0.05	-0.15	-0.05	0.00	0.00	0.66	-0.16	-0.52	-0.36
Income Tax Expense	-	-	-	-	-	-	-	0.00	0.00	0.18
Other Gains / (Losses), net	-	-	-	-	-	-	-	-5.20	-0.47	0.00
Basic Earnings per Share	($5.96)	($6.68)	($2.23)	($2.09)	($2.42)	($2.80)	($3.15)	($3.69)	($3.69)	($4.95)
Weighted Average Basic Shares Outstanding	1.01M	1.37M	12.14M	24.18M	30.45M	38.44M	51.98M	58.07M	80.78M	94.06M
Diluted Earnings per Share	($5.96)	($6.68)	($2.23)	($2.09)	($2.42)	($2.80)	($3.15)	($3.69)	($3.69)	($4.95)
Weighted Average Diluted Shares Outstanding	1.01M	1.37M	12.14M	24.18M	30.45M	38.44M	51.98M	58.07M	80.78M	94.06M
Weighted Average Basic & Diluted Shares Outstanding	1.01M	1.37M	12.14M	24.18M	30.45M	38.44M	53.91M	69.60M	93.05M	104.71M

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-57	-61	-67	-74	-77	-83	-97	-116	-130	-123	-128
Consolidated Net Income / (Loss)	-57	-60	-67	-74	-77	-81	-97	-116	-130	-123	-128
Net Income / (Loss) Continuing Operations	-57	-60	-67	-74	-77	-81	-97	-116	-130	-123	-128
Total Pre-Tax Income	-57	-60	-67	-74	-77	-81	-97	-116	-130	-123	-128
Total Operating Income	-59	-63	-74	-83	-88	-95	-111	-129	-143	-134	-140
Total Gross Profit	0.35	-	0.64	0.40	0.00	-	0.72	1.03	0.14	5.09	11
Total Revenue	0.35	-	0.64	0.40	0.00	-	0.72	1.03	0.14	6.16	11
Operating Revenue	0.35	-	0.64	0.40	0.00	-	0.72	1.03	0.14	6.16	11
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	1.08	0.20
Operating Cost of Revenue	-	-	-	-	-	-	0.00	-	-	-	0.20
Total Operating Expenses	59	63	74	83	88	95	112	130	143	139	151
Selling, General & Admin Expense	15	17	21	25	26	28	36	50	52	54	51
Research & Development Expense	44	46	53	58	62	67	76	80	90	85	100
Total Other Income / (Expense), net	1.52	2.56	6.60	8.73	11	14	15	13	12	11	13
Interest & Investment Income	1.57	2.52	6.85	8.74	11	14	15	13	13	11	13
Other Income / (Expense), net	-0.05	-	-0.25	-0.01	-0.04	-	-0.20	0.02	-0.05	-0.13	-0.13
Basic Earnings per Share	($1.01)	($0.89)	($0.93)	($0.94)	($0.96)	($0.86)	($1.04)	($1.23)	($1.38)	($1.30)	($1.23)
Weighted Average Basic Shares Outstanding	56.81M	58.07M	72.29M	79.01M	80.09M	80.78M	93.10M	93.79M	94.22M	94.06M	104.10M
Diluted Earnings per Share	($1.01)	($0.89)	($0.93)	($0.94)	($0.96)	($0.86)	($1.04)	($1.23)	($1.38)	($1.30)	($1.23)
Weighted Average Diluted Shares Outstanding	56.81M	58.07M	72.29M	79.01M	80.09M	80.78M	93.10M	93.79M	94.22M	94.06M	104.10M
Weighted Average Basic & Diluted Shares Outstanding	66.80M	69.60M	78.86M	80.04M	92.74M	93.05M	93.68M	94.18M	94.89M	104.71M	105.44M

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-5.71	2.04	31	-4.65	53	108	-167	22	210	-163
Net Cash From Operating Activities	-5.47	-9.48	-19	-46	-62	-89	-115	-169	-230	-378
Net Cash From Continuing Operating Activities	-5.47	-9.48	-19	-46	-62	-89	-115	-169	-230	-378
Net Income / (Loss) Continuing Operations	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298	-465
Consolidated Net Income / (Loss)	-6.02	-9.16	-27	-50	-74	-108	-164	-215	-298	-465
Depreciation Expense	0.09	0.13	0.47	0.89	0.95	0.92	0.98	1.10	2.79	3.89
Amortization Expense	-	-	-0.43	-1.23	-0.23	0.42	0.03	-8.27	-15	-15
Non-Cash Adjustments To Reconcile Net Income	0.27	0.27	2.32	6.52	11	17	29	47	73	94
Changes in Operating Assets and Liabilities, net	0.19	-0.72	5.30	-2.13	0.38	1.10	19	5.75	7.41	4.84
Net Cash From Investing Activities	-0.19	-0.30	-119	42	0.22	-56	-174	-200	-575	174
Net Cash From Continuing Investing Activities	-0.19	-0.30	-119	42	0.22	-56	-174	-200	-575	174
Purchase of Property, Plant & Equipment	-0.19	-0.30	-1.06	-0.49	-0.19	-0.44	-1.66	-4.69	-3.84	-5.76
Purchase of Investments	-	-	-118	-108	-136	-125	-330	-528	-1,147	-1,004
Sale and/or Maturity of Investments	-	-	0.00	150	136	69	157	337	576	1,184
Other Investing Activities, net	-	-	-	-	-	-	0.00	-5.00	0.00	0.00
Net Cash From Financing Activities	-0.05	12	170	0.07	115	253	122	391	1,015	41
Net Cash From Continuing Financing Activities	-0.05	12	170	0.07	115	253	122	391	1,015	41
Repurchase of Common Equity	-	-	-	-	-	-	-	-0.54	-15	0.00
Issuance of Common Equity	-	-	106	0.00	114	250	117	370	985	0.00
Other Financing Activities, net	-	0.07	0.45	0.13	0.29	3.14	4.72	22	45	41

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	103	-88	341	-94	15	-53	-170	-41	57	-9.76	13
Net Cash From Operating Activities	-41	-39	-53	-46	-63	-65	-88	-86	-111	-93	-125
Net Cash From Continuing Operating Activities	-41	-39	-53	-46	-63	-65	-88	-86	-111	-93	-125
Net Income / (Loss) Continuing Operations	-57	-60	-67	-74	-77	-81	-97	-116	-130	-123	-128
Consolidated Net Income / (Loss)	-57	-60	-67	-74	-77	-81	-97	-116	-130	-123	-128
Depreciation Expense	0.27	0.26	0.47	0.75	0.77	0.79	0.93	0.96	1.01	0.99	1.16
Amortization Expense	-1.25	-3.58	-3.85	-3.41	-3.51	-4.16	-3.56	-4.71	-3.60	-2.73	-2.22
Non-Cash Adjustments To Reconcile Net Income	12	17	15	20	19	20	20	27	21	25	29
Changes in Operating Assets and Liabilities, net	4.85	8.30	2.69	11	-2.15	-0.31	-9.54	6.60	1.08	6.69	-26
Net Cash From Investing Activities	-193	-87	0.31	-54	21	-542	-86	38	165	57	-252
Net Cash From Continuing Investing Activities	-193	-87	0.31	-54	21	-542	-86	38	165	57	-253
Purchase of Property, Plant & Equipment	-3.50	-0.94	-1.33	-0.96	-0.53	-1.03	-1.24	-3.20	-0.86	-0.46	-1.28
Purchase of Investments	-278	-168	-100	-192	-130	-725	-391	-183	-217	-214	-554
Sale and/or Maturity of Investments	88	87	101	139	151	184	306	224	382	271	303
Net Cash From Financing Activities	338	38	394	5.50	57	554	4.44	7.06	3.08	26	390
Net Cash From Continuing Financing Activities	338	38	394	5.50	57	554	4.44	7.06	3.08	26	390
Repurchase of Common Equity	-	-	-	-	-	-	0.00	-	-	-	-0.58
Issuance of Common Equity	329	29	383	-4.31	47	544	0.00	-	-	-	381
Other Financing Activities, net	8.92	9.17	10	9.81	11	9.54	4.44	7.06	3.08	26	9.94
Other Net Changes in Cash	-	-	-	-	-	-	-	-	-	-	-0.01

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	16	130	183	351	352	635	1,435	1,126
Total Current Assets	15	123	177	345	345	574	1,375	1,048
Cash & Equivalents	14	40	93	201	33	55	265	102
Short-Term Investments	-	78	78	133	302	504	1,090	926
Accounts Receivable	-	-	-	-	-	-	0.00	0.59
Inventories, net	-	-	-	-	-	-	0.00	2.02
Prepaid Expenses	0.97	4.95	6.61	11	11	16	21	18
Plant, Property, & Equipment, net	0.40	3.95	3.18	2.83	3.50	11	12	14
Total Noncurrent Assets	0.03	3.09	2.77	3.47	3.49	50	47	64
Other Noncurrent Operating Assets	0.03	3.09	2.77	2.46	3.49	50	47	64
Total Liabilities & Shareholders' Equity	16	130	183	351	352	635	1,435	1,126
Total Liabilities	0.92	13	15	19	36	96	110	134
Total Current Liabilities	0.90	8.34	10	16	28	44	60	85
Accounts Payable	0.40	5.50	5.59	8.47	15	23	21	42
Accrued Expenses	0.18	2.12	4.07	6.59	9.08	15	29	36
Current Deferred Revenue	-	-	-	0.00	2.24	2.06	2.18	1.24
Other Current Liabilities	-	0.72	0.84	0.94	1.05	4.17	7.15	6.49
Total Noncurrent Liabilities	0.02	4.90	4.04	3.08	8.13	52	50	49
Noncurrent Deferred Revenue	0.02	-	-	0.00	6.10	4.75	4.70	3.81
Other Noncurrent Operating Liabilities	-	4.85	4.01	3.07	2.02	48	45	45
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-15	117	169	332	316	539	1,325	992
Total Preferred & Common Equity	-15	117	169	332	316	539	1,325	992
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-15	117	169	332	316	539	1,325	992
Common Stock	1.24	211	337	608	759	1,192	2,276	2,408
Retained Earnings	-16	-94	-168	-275	-439	-654	-952	-1,417
Accumulated Other Comprehensive Income / (Loss)	-	0.15	0.03	-0.38	-3.93	0.98	0.96	1.87
Other Equity Adjustments	-	-	-	-	-	-	0.00	-0.11

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	385	314	293	642	978	936	937	1,361	1,290	1,196	1,401
Total Current Assets	378	305	285	576	917	875	878	1,291	1,217	1,121	1,322
Cash & Equivalents	31	41	40	143	396	302	317	95	54	111	114
Short-Term Investments	337	255	225	412	505	561	545	1,180	1,143	981	1,177
Accounts Receivable	-	-	-	-	-	-	-	-	-	-	5.68
Inventories, net	-	-	-	-	-	-	-	-	-	-	3.06
Prepaid Expenses	9.96	9.28	20	21	16	12	15	16	20	28	22
Plant, Property, & Equipment, net	3.56	3.27	3.22	9.76	12	12	12	13	15	14	13
Total Noncurrent Assets	2.99	5.34	5.22	56	49	49	48	58	58	60	65
Other Noncurrent Operating Assets	2.99	5.34	5.22	51	49	49	48	58	58	60	65
Total Liabilities & Shareholders' Equity	385	314	293	642	978	936	937	1,361	1,290	1,196	1,401
Total Liabilities	34	34	39	94	103	105	104	107	118	124	121
Total Current Liabilities	25	26	33	40	52	54	54	57	68	74	71
Accounts Payable	13	16	21	22	29	24	18	32	38	34	37
Accrued Expenses	7.72	6.83	8.60	13	15	20	26	17	22	32	26
Current Deferred Revenue	2.32	2.12	2.08	1.66	2.46	2.56	1.69	2.21	1.90	1.64	1.27
Other Current Liabilities	1.02	1.08	1.11	3.99	5.79	7.45	7.41	6.88	6.61	6.44	6.54
Total Noncurrent Liabilities	8.95	7.36	6.53	53	51	50	51	50	50	50	50
Noncurrent Deferred Revenue	6.65	5.62	5.07	5.14	4.74	4.32	5.20	4.31	3.99	4.11	3.35
Other Noncurrent Operating Liabilities	2.30	1.74	1.46	48	47	46	46	46	46	46	46
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	351	280	254	548	875	831	833	1,254	1,172	1,072	1,281
Total Preferred & Common Equity	351	280	254	548	875	831	833	1,254	1,172	1,072	1,281
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	351	280	254	548	875	831	833	1,254	1,172	1,072	1,281
Common Stock	751	768	792	1,142	1,595	1,626	1,702	2,301	2,335	2,365	2,828
Retained Earnings	-394	-485	-536	-594	-721	-795	-872	-1,049	-1,165	-1,295	-1,545
Accumulated Other Comprehensive Income / (Loss)	-5.01	-2.51	-1.71	-0.87	0.15	-0.19	2.04	2.00	1.62	2.19	-1.25
Other Equity Adjustments	-	-	-	-	-	-	-	-	-0.11	-0.11	-1.03

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	247.20%	18.73%	-50.86%	-88.10%	659.15%	339.42%	-15.28%	-74.11%	640.71%
EBITDA Growth	0.00%	-51.97%	-218.61%	-88.11%	-36.90%	-43.28%	-56.27%	-37.14%	-54.22%	-50.39%
EBIT Growth	0.00%	-51.78%	-214.58%	-86.68%	-39.11%	-43.69%	-55.27%	-33.21%	-52.34%	-52.38%
NOPAT Growth	0.00%	-51.01%	-214.56%	-87.50%	-39.24%	-43.69%	-55.88%	-32.60%	-52.22%	-52.50%
Net Income Growth	0.00%	-52.13%	-196.11%	-85.96%	-46.39%	-45.83%	-52.28%	-30.88%	-39.10%	-55.93%
EPS Growth	0.00%	-12.08%	66.62%	6.28%	-15.79%	-15.70%	-12.50%	-17.14%	0.00%	-34.15%
Operating Cash Flow Growth	0.00%	-73.35%	-105.29%	-138.35%	-33.73%	-42.82%	-30.05%	-44.36%	-35.88%	-64.18%
Free Cash Flow Firm Growth	0.00%	0.00%	-185.26%	-85.76%	-42.08%	-44.09%	-37.03%	-50.70%	-47.63%	-56.45%
Invested Capital Growth	0.00%	0.00%	-100.00%	0.00%	-56.50%	-41.41%	-552.61%	-10.07%	-49.43%	-20.30%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	1,418.31%	-23.40%	-15.01%	0.00%	401.37%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-6,361.43%	-17,009.34%	-9.21%	-11.02%	-8.84%	-10.24%	-7.57%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-9.23%	-10.59%	-7.35%	-10.63%	-8.12%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-9.23%	-11.02%	-7.28%	-10.46%	-8.15%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-9.29%	-9.48%	-7.57%	-7.38%	-9.98%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-2.19%	-5.00%	-1.65%	0.81%	-9.76%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-21.92%	-19.10%	-4.18%	-8.53%	-11.96%	-2.03%	-13.09%	-8.70%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-1,931.36%	-8.26%	-15.35%	-2.21%	-15.63%	-3.53%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	41.72%	-592.71%	-1,146.42%	-6.52%	-72.07%	-0.26%	-73.63%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	86.02%
EBITDA Margin	-1,010.70%	-442.40%	-1,187.19%	-4,545.18%	-52,276.06%	-9,866.23%	-3,508.72%	-5,680.04%	-33,832.44%	-6,869.30%
Operating Margin	-1,026.15%	-446.31%	-1,182.45%	-4,512.32%	-52,783.80%	-9,990.91%	-3,544.06%	-5,547.17%	-32,613.47%	-6,714.77%
EBIT Margin	-1,026.32%	-448.66%	-1,188.76%	-4,516.51%	-52,783.80%	-9,990.91%	-3,530.19%	-5,551.13%	-32,663.43%	-6,719.41%
Profit (Net Income) Margin	-1,021.90%	-447.78%	-1,116.76%	-4,226.49%	-51,980.28%	-9,985.25%	-3,460.38%	-5,345.85%	-28,720.69%	-6,046.22%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	99.80%	100.09%	100.00%	100.00%	100.00%	100.04%
Interest Burden Percent	99.57%	99.80%	93.94%	93.58%	98.68%	99.85%	98.02%	96.30%	87.93%	89.95%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2,629.18%	-8,270.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,590.17%	-8,171.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	2,504.41%	7,900.91%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-124.77%	-369.46%	-86.09%	-51.61%	-42.98%	-50.57%	-50.16%	-32.02%	-40.17%
Cash Return on Invested Capital (CROIC)	0.00%	-2,829.18%	-8,070.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-58.82%	-370.09%	-82.66%	-47.77%	-40.30%	-47.56%	-45.12%	-32.79%	-40.39%
Return on Assets (ROA)	0.00%	-58.71%	-347.67%	-77.35%	-47.04%	-40.28%	-46.62%	-43.45%	-28.83%	-36.34%
Return on Common Equity (ROCE)	0.00%	127.70%	378.12%	-86.09%	-51.61%	-42.98%	-50.57%	-50.16%	-32.02%	-40.17%
Return on Equity Simple (ROE_SIMPLE)	0.00%	60.96%	0.00%	-43.04%	-43.70%	-32.43%	-51.82%	-39.79%	-22.52%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.23	-6.39	-20	-38	-52	-75	-118	-156	-237	-362
NOPAT Margin	-718.30%	-312.42%	-827.72%	-3,158.63%	-36,948.66%	-6,993.64%	-2,480.84%	-3,883.02%	-22,829.43%	-4,700.34%
Net Nonoperating Expense Percent (NNEP)	0.00%	-39.01%	-98.90%	-21.52%	-14.76%	-12.76%	-13.87%	-13.14%	-6.40%	-8.70%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-37.15%	-28.90%	-17.90%	-36.46%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	13.98%
SG&A Expenses to Revenue	260.27%	94.82%	274.26%	1,133.19%	12,694.37%	2,275.05%	894.95%	1,447.65%	9,599.33%	2,486.11%
R&D to Revenue	865.87%	451.49%	1,008.20%	3,479.13%	40,139.44%	7,815.86%	2,749.10%	4,199.53%	23,114.15%	4,314.68%
Operating Expenses to Revenue	1,126.15%	546.31%	1,282.45%	4,612.32%	52,728.17%	10,099.81%	3,644.06%	5,647.17%	32,713.47%	6,800.79%
Earnings before Interest and Taxes (EBIT)	-6.05	-9.18	-29	-54	-75	-108	-167	-223	-339	-517
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.95	-9.05	-29	-54	-74	-106	-166	-228	-352	-529
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	5.19	2.75	4.07	3.11	3.56	2.08	2.53
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	5.19	2.75	4.07	3.11	3.56	2.08	2.53
Price to Revenue (P/Rev)	173.17	49.88	296.90	509.42	3,271.37	1,251.83	207.88	477.97	2,652.90	326.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	241.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	57.46	296.90	410.18	2,067.99	941.33	137.28	338.66	1,349.17	192.51
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.97	-0.97	-1.01	-1.01	-1.01	-1.03	-1.04	-1.03	-1.03
Leverage Ratio	0.00	1.06	1.06	1.11	1.10	1.07	1.08	1.15	1.11	1.11
Compound Leverage Factor	0.00	1.06	1.00	1.04	1.08	1.07	1.06	1.11	0.98	0.99
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	202.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-102.34%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	64.35	0.00	26.24	17.65	41.47	14.26	10.37	14.46	8.98
Noncontrolling Interest Sharing Ratio	0.00%	202.34%	202.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	16.91	0.00	14.79	16.92	21.55	12.45	13.07	23.04	12.32
Quick Ratio	0.00	15.82	0.00	14.20	16.29	20.86	12.06	12.71	22.69	12.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-6.87	-20	-36	-52	-75	-102	-154	-227	-356
Operating Cash Flow to CapEx	-2,877.89%	-3,118.09%	-1,837.49%	-9,427.03%	-33,347.85%	-20,318.35%	-6,956.82%	-3,547.50%	-5,878.51%	-6,558.87%
Free Cash Flow to Firm to Interest Expense	0.00	-859.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-497.09	-1,184.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-514.36	-1,222.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.13	0.31	0.02	0.00	0.00	0.01	0.01	0.00	0.01
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	5.11	0.00	0.00	0.04	0.36	1.50	0.56	0.09	0.58
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10,725.95
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-10,725.95
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	0.49	0.00	-1.25	-1.96	-2.77	-18	-20	-30	-36
Invested Capital Turnover	0.00	8.42	9.99	-1.90	-0.09	-0.46	-0.45	-0.21	-0.04	-0.23
Increase / (Decrease) in Invested Capital	0.00	0.49	-0.49	-1.25	-0.71	-0.81	-15	-1.82	-9.85	-6.04
Enterprise Value (EV)	0.00	118	721	489	294	1,015	650	1,359	1,402	1,482
Market Capitalization	102	102	721	608	465	1,349	985	1,918	2,756	2,509
Book Value per Share	$0.00	($10.96)	$0.00	$4.84	$5.13	$6.99	$5.88	$8.07	$14.29	$10.45
Tangible Book Value per Share	$0.00	($10.96)	$0.00	$4.84	$5.13	$6.99	$5.88	$8.07	$14.29	$10.45
Total Capital	0.00	15	0.00	117	169	332	316	539	1,325	992
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-14	0.00	-118	-171	-335	-334	-559	-1,355	-1,028
Capital Expenditures (CapEx)	0.19	0.30	1.06	0.49	0.19	0.44	1.66	4.69	3.84	5.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.08	0.00	-3.39	-3.88	-4.98	-17	-28	-39	-65
Debt-free Net Working Capital (DFNWC)	0.00	14	0.00	115	167	329	317	530	1,316	963
Net Working Capital (NWC)	0.00	14	0.00	115	167	329	317	530	1,316	963
Net Nonoperating Expense (NNE)	1.79	2.77	7.02	13	21	32	46	59	61	104
Net Nonoperating Obligations (NNO)	0.00	-14	0.00	-118	-171	-335	-334	-559	-1,355	-1,028
Total Depreciation and Amortization (D&A)	0.09	0.13	0.04	-0.34	0.72	1.34	1.02	-5.17	-12	-12
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	3.72%	0.00%	-284.41%	-2,730.28%	-462.15%	-358.12%	-706.30%	-3,740.62%	-839.64%
Debt-free Net Working Capital to Revenue	0.00%	697.70%	0.00%	9,639.48%	117,607.75%	30,493.97%	6,701.73%	13,212.33%	126,631.76%	12,516.50%
Net Working Capital to Revenue	0.00%	697.70%	0.00%	9,639.48%	117,607.75%	30,493.97%	6,701.73%	13,212.33%	126,631.76%	12,516.50%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.96)	($6.68)	($2.23)	$0.00	($2.42)	($2.80)	($3.15)	($3.69)	($3.69)	($4.95)
Adjusted Weighted Average Basic Shares Outstanding	1.01M	1.37M	24.10M	0.00	33.03M	47.78B	51.98M	58.07M	80.78M	94.06M
Adjusted Diluted Earnings per Share	($5.96)	($6.68)	($2.23)	$0.00	($2.42)	($2.80)	($3.15)	($3.69)	($3.69)	($4.95)
Adjusted Weighted Average Diluted Shares Outstanding	1.01M	1.37M	24.10M	0.00	33.03M	47.78B	51.98M	58.07M	80.78M	94.06M
Adjusted Basic & Diluted Earnings per Share	($5.96)	($6.68)	($2.23)	$0.00	($2.42)	($2.80)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.01M	1.37M	12.14M	0.00	30.45M	38.44M	53.91M	69.60M	93.05M	104.71M
Normalized Net Operating Profit after Tax (NOPAT)	-4.23	-6.39	-20	-38	-52	-75	-118	-156	-237	-362
Normalized NOPAT Margin	-718.30%	-312.42%	-827.72%	-3,158.63%	-36,948.66%	-6,993.64%	-2,480.84%	-3,883.02%	-22,829.43%	-4,700.34%
Pre Tax Income Margin	-1,021.90%	-447.78%	-1,116.76%	-4,226.49%	-52,085.92%	-9,976.35%	-3,460.38%	-5,345.85%	-28,720.69%	-6,043.88%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-549.55	-1,146.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-384.62	-798.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-566.82	-1,184.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-401.89	-836.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	104,705,330.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	104,705,330.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-1.22
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-24.45%	0.00%	-76.11%	-59.62%	-100.00%	0.00%	-43.59%	158.40%	0.00%	0.00%	1,386.70%
EBITDA Growth	-38.55%	-38.53%	-59.47%	-59.08%	-50.95%	-48.71%	-49.13%	-55.47%	-60.33%	-37.82%	-23.92%
EBIT Growth	-35.94%	-31.76%	-53.26%	-55.97%	-48.80%	-51.21%	-51.27%	-55.92%	-62.39%	-40.89%	-25.90%
NOPAT Growth	-35.72%	-31.76%	-53.26%	-56.21%	-48.87%	-51.21%	-51.51%	-55.96%	-62.40%	-41.08%	-26.01%
Net Income Growth	-37.05%	-33.58%	-45.52%	-45.27%	-33.71%	-34.11%	-44.59%	-56.15%	-69.33%	-52.39%	-32.11%
EPS Growth	-29.49%	-7.23%	-9.41%	0.00%	4.95%	3.37%	-11.83%	-30.85%	-43.75%	-51.16%	-18.27%
Operating Cash Flow Growth	-7.43%	-9.40%	-29.81%	0.26%	-51.97%	-67.92%	-67.35%	-80.19%	-76.24%	-38.93%	-40.98%
Free Cash Flow Firm Growth	-254.77%	-134.00%	-19.38%	26.22%	7.18%	-34.34%	-102.23%	-168.82%	-151.18%	-54.97%	-29.79%
Invested Capital Growth	31.87%	-10.07%	-64.82%	-209.13%	-156.46%	-49.43%	20.76%	21.30%	30.54%	-20.30%	48.31%
Revenue Q/Q Growth	-64.98%	0.00%	0.00%	-37.66%	-100.00%	0.00%	0.00%	185.60%	-86.13%	4,208.39%	74.23%
EBITDA Q/Q Growth	-11.70%	-9.96%	-16.55%	-11.12%	-6.00%	-8.33%	-17.26%	-15.46%	-9.32%	6.67%	-4.46%
EBIT Q/Q Growth	-11.20%	-6.15%	-17.35%	-12.60%	-6.08%	-7.87%	-17.80%	-15.67%	-10.49%	6.20%	-5.02%
NOPAT Q/Q Growth	-11.29%	-6.24%	-17.35%	-12.59%	-6.06%	-7.91%	-17.58%	-15.89%	-10.44%	6.26%	-5.02%
Net Income Q/Q Growth	-12.71%	-4.59%	-11.37%	-10.65%	-3.74%	-4.90%	-20.07%	-19.49%	-12.50%	5.59%	-4.10%
EPS Q/Q Growth	-7.45%	11.88%	-4.49%	-1.08%	-2.13%	10.42%	-20.93%	-18.27%	-12.20%	5.80%	5.38%
Operating Cash Flow Q/Q Growth	9.61%	6.83%	-37.23%	13.70%	-37.72%	-2.95%	-36.77%	2.94%	-28.97%	16.09%	-34.23%
Free Cash Flow Firm Q/Q Growth	4.75%	9.98%	1.91%	12.28%	-19.84%	-30.29%	-47.65%	-16.61%	-11.97%	19.61%	-23.66%
Invested Capital Q/Q Growth	-11.17%	-72.07%	-30.67%	-23.67%	7.77%	-0.26%	30.71%	-22.84%	18.60%	-73.63%	70.23%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	0.00%	100.00%	100.00%	0.00%	0.00%	100.00%	100.00%	100.00%	82.54%	98.14%
EBITDA Margin	-17,341.91%	0.00%	-12,015.94%	-21,416.29%	0.00%	0.00%	-31,872.30%	-12,885.26%	-101,555.24%	-2,199.82%	-1,318.88%
Operating Margin	-17,045.38%	0.00%	-11,488.91%	-20,747.62%	0.00%	0.00%	-30,860.11%	-12,522.99%	-99,710.49%	-2,169.55%	-1,307.79%
EBIT Margin	-17,060.69%	0.00%	-11,488.91%	-20,750.88%	0.00%	0.00%	-30,916.34%	-12,521.05%	-99,744.76%	-2,171.58%	-1,309.01%
Profit (Net Income) Margin	-16,606.36%	0.00%	-10,457.81%	-18,560.15%	0.00%	0.00%	-26,807.20%	-11,216.00%	-90,972.73%	-1,993.43%	-1,191.03%
Tax Burden Percent	100.00%	99.91%	100.38%	100.00%	100.00%	99.69%	100.00%	100.00%	100.00%	100.15%	100.00%
Interest Burden Percent	97.34%	96.00%	90.68%	89.44%	87.47%	85.33%	86.71%	89.58%	91.21%	91.66%	90.99%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-44.36%	-50.16%	-40.76%	-47.66%	-40.26%	-32.02%	-30.84%	-36.94%	-44.42%	-40.17%	-39.17%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-156.97%	0.00%	-35.10%	-46.78%	0.00%	0.00%	-20.09%	-15.67%	-143.53%	-13.05%	-16.78%
Return on Assets (ROA)	-152.79%	0.00%	-31.95%	-41.84%	0.00%	0.00%	-17.42%	-14.03%	-130.91%	-11.98%	-15.27%
Return on Common Equity (ROCE)	-44.36%	-50.16%	-40.76%	-47.66%	-40.26%	-32.02%	-30.84%	-36.94%	-44.42%	-40.17%	-39.17%
Return on Equity Simple (ROE_SIMPLE)	-36.41%	0.00%	-26.91%	-31.12%	-33.36%	0.00%	-26.18%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-41	-44	-51	-58	-61	-66	-78	-90	-100	-94	-98
NOPAT Margin	-11,931.76%	0.00%	-8,042.23%	-14,523.33%	0.00%	0.00%	-21,602.08%	-8,766.09%	-69,797.34%	-1,518.69%	-915.45%
Net Nonoperating Expense Percent (NNEP)	-3.49%	-3.63%	-2.58%	-2.86%	-2.16%	-1.49%	-1.73%	-2.45%	-3.10%	-2.46%	-2.31%
Return On Investment Capital (ROIC_SIMPLE)	-	-8.14%	-	-	-	-5.01%	-6.22%	-7.71%	-9.31%	-9.43%	-7.67%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	17.46%	1.86%
SG&A Expenses to Revenue	4,475.14%	0.00%	3,254.38%	6,225.06%	0.00%	0.00%	9,841.00%	4,834.34%	36,548.95%	871.58%	473.55%
R&D to Revenue	12,670.23%	0.00%	8,334.53%	14,622.56%	0.00%	0.00%	21,119.11%	7,788.65%	63,261.54%	1,380.51%	932.37%
Operating Expenses to Revenue	17,145.38%	0.00%	11,588.91%	20,847.62%	0.00%	0.00%	30,960.11%	12,622.99%	99,810.49%	2,252.09%	1,405.93%
Earnings before Interest and Taxes (EBIT)	-59	-63	-74	-83	-88	-95	-112	-129	-143	-134	-141
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-60	-66	-77	-85	-91	-98	-115	-133	-145	-136	-142
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.93	3.56	2.88	2.91	3.31	2.08	1.44	1.32	2.09	2.53	1.53
Price to Tangible Book Value (P/TBV)	2.93	3.56	2.88	2.91	3.31	2.08	1.44	1.32	2.09	2.53	1.53
Price to Revenue (P/Rev)	339.53	477.97	1,278.36	1,743.38	2,651.34	2,652.90	2,379.08	1,113.81	1,462.74	326.07	110.57
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	221.08	338.66	821.94	1,120.31	1,821.05	1,349.17	701.95	253.99	750.82	192.51	37.65
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.03	-1.04	-1.04	-1.04	-1.03	-1.03	-1.02	-1.03	-1.03	-1.03	-1.01
Leverage Ratio	1.14	1.15	1.12	1.13	1.14	1.11	1.10	1.11	1.12	1.11	1.09
Compound Leverage Factor	1.11	1.11	1.01	1.01	1.00	0.95	0.95	1.00	1.02	1.01	0.99
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	9.67	11.20	14.45	13.40	15.28	15.02	9.85	7.36	10.02	10.10	8.94
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	14.23	13.07	17.72	16.09	16.38	23.04	22.53	17.80	15.12	12.32	18.60
Quick Ratio	13.71	12.71	17.40	15.87	16.11	22.69	22.23	17.49	14.73	12.09	18.25
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-47	-42	-41	-36	-43	-56	-83	-97	-109	-88	-108
Operating Cash Flow to CapEx	-1,181.11%	-4,119.25%	-3,968.17%	-4,776.65%	-11,898.30%	-6,285.13%	-7,138.98%	-2,681.17%	-12,829.43%	-20,284.06%	-9,712.07%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.71	0.56	0.26	0.18	0.10	0.09	0.06	0.10	0.12	0.58	1.36
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.04
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10,725.95	9,883.46
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-10,725.95	-9,883.46
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-12	-20	-26	-32	-30	-30	-21	-25	-21	-36	-11
Invested Capital Turnover	-0.33	-0.21	-0.09	-0.07	-0.05	-0.04	-0.03	-0.05	-0.06	-0.23	-1.13
Increase / (Decrease) in Invested Capital	5.41	-1.82	-10	-22	-18	-9.85	5.40	6.86	9.07	-6.04	9.96
Enterprise Value (EV)	1,044	1,359	1,623	1,552	1,892	1,402	533	354	1,153	1,482	667
Market Capitalization	1,603	1,918	2,523	2,415	2,755	2,756	1,808	1,550	2,245	2,509	1,958
Book Value per Share	$10.02	$8.07	$12.57	$10.53	$10.41	$14.29	$13.48	$12.51	$11.38	$10.45	$12.23
Tangible Book Value per Share	$10.02	$8.07	$12.57	$10.53	$10.41	$14.29	$13.48	$12.51	$11.38	$10.45	$12.23
Total Capital	548	539	875	831	833	1,325	1,254	1,172	1,072	992	1,281
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-559	-559	-901	-863	-863	-1,355	-1,275	-1,197	-1,093	-1,028	-1,291
Capital Expenditures (CapEx)	3.50	0.94	1.33	0.96	0.53	1.03	1.24	3.20	0.86	0.46	1.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	-28	-36	-43	-39	-39	-41	-48	-46	-65	-40
Debt-free Net Working Capital (DFNWC)	535	530	865	820	824	1,316	1,234	1,149	1,047	963	1,251
Net Working Capital (NWC)	535	530	865	820	824	1,316	1,234	1,149	1,047	963	1,251
Net Nonoperating Expense (NNE)	16	16	15	16	15	14	19	25	30	29	30
Net Nonoperating Obligations (NNO)	-559	-559	-901	-863	-863	-1,355	-1,275	-1,197	-1,093	-1,028	-1,291
Total Depreciation and Amortization (D&A)	-0.97	-3.32	-3.37	-2.66	-2.74	-3.38	-3.45	-3.76	-2.59	-1.74	-1.06
Debt-free, Cash-free Net Working Capital to Revenue	-409.91%	-706.30%	-1,798.38%	-3,072.49%	-3,719.25%	-3,740.62%	-5,378.95%	-3,447.70%	-2,975.31%	-839.64%	-225.76%
Debt-free Net Working Capital to Revenue	11,336.23%	13,212.33%	43,843.01%	59,234.58%	79,309.43%	126,631.76%	162,334.74%	82,533.62%	68,216.29%	12,516.50%	7,066.46%
Net Working Capital to Revenue	11,336.23%	13,212.33%	43,843.01%	59,234.58%	79,309.43%	126,631.76%	162,334.74%	82,533.62%	68,216.29%	12,516.50%	7,066.46%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.01)	($0.89)	($0.93)	($0.94)	($0.96)	($0.86)	($1.04)	($1.23)	($1.38)	($1.30)	($1.23)
Adjusted Weighted Average Basic Shares Outstanding	56.81M	58.07M	72.29M	79.01M	80.09M	80.78M	93.10M	93.79M	94.22M	94.06M	104.10M
Adjusted Diluted Earnings per Share	($1.01)	($0.89)	($0.93)	($0.94)	($0.96)	($0.86)	($1.04)	($1.23)	($1.38)	($1.30)	($1.23)
Adjusted Weighted Average Diluted Shares Outstanding	56.81M	58.07M	72.29M	79.01M	80.09M	80.78M	93.10M	93.79M	94.22M	94.06M	104.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	66.80M	69.60M	78.86M	80.04M	92.74M	93.05M	93.68M	94.18M	94.89M	104.71M	105.44M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-44	-51	-58	-61	-66	-78	-90	-100	-94	-98
Normalized NOPAT Margin	-11,931.76%	0.00%	-8,042.23%	-14,523.33%	0.00%	0.00%	-21,602.08%	-8,766.09%	-69,797.34%	-1,518.69%	-915.45%
Pre Tax Income Margin	-16,606.36%	0.00%	-10,418.59%	-18,560.15%	0.00%	0.00%	-26,807.20%	-11,216.00%	-90,972.73%	-1,990.50%	-1,191.03%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.12%

Financials Breakdown Chart

Key Financial Trends

Crinetics (CRNX) shows several clear trends across the last four years. The company has substantial liquidity from investments and equity, but operating performance remains negative with ongoing cash burn. Below are the most impactful points, organized with positives first, then neutral, then negatives.

Crinetics holds a large liquidity buffer, with Total Current Assets around $1.12B as of Q3 2025, including about $981M in short-term investments and roughly $111M in cash and equivalents.
Financing activity has contributed meaningful cash in recent quarters, with Net Cash From Financing Activities around $26.0M in Q4 2025, supporting liquidity amid ongoing losses.
In investing activities, Crinetics saw a substantial inflow from the sale/maturity of investments in Q3 2025 (~$382.4M), boosting cash despite operating losses.
Equity base remains robust, with Total Common Equity around $1.07B as of Q3 2025, reflecting a sizable common stock position backing the balance sheet.
Revenue remains small and volatile: Q4 2025 revenue of about $6.16M follows modest prior quarters, suggesting episodic or milestone-related inflows rather than steady top-line growth.
Operating cash flow is consistently negative across quarters, indicating ongoing cash burn to fund operations despite some revenue recognition.
Cumulative losses are evident, as retained earnings are heavily negative (approximately -$1.29B by Q3 2025), pointing to sustained funding needs to support ongoing activity.
Shares outstanding metrics indicate potential dilution considerations, with weighted-average shares around the 93–105 million range and persistently negative earnings per share.
Net income is persistently negative across quarters, e.g., Q4 2025 net income of about -$122.8M and Q3 2025 around -$130.1M, highlighting ongoing profitability challenges.
Operating expenses far exceed revenue in 2025, with Total Operating Expenses around $138.8M in Q4 2025 and -133.7M in Total Operating Income, underscoring a continued gap between spending and topline growth.

05/26/26 10:17 PM ETAI Generated. May Contain Errors.

Crinetics Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Crinetics Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Crinetics Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$465.32 million in 2025, rising from -$6.02 million in 2016. The previous period was -$298.41 million in 2024. Find out what analysts predict for Crinetics Pharmaceuticals in the coming months.

Crinetics Pharmaceuticals' total operating income in 2025 was -$516.77 million, based on the following breakdown:

Total Gross Profit: $6.62 million
Total Operating Expenses: $523.39 million

Over the last 9 years, Crinetics Pharmaceuticals' total revenue changed from $589 thousand in 2016 to $7.70 million in 2025, a change of 1,206.6%.

Crinetics Pharmaceuticals' total liabilities were at $134.17 million at the end of 2025, a 22.2% increase from 2024, and a 14,484.1% increase since 2017.

In the past 7 years, Crinetics Pharmaceuticals' cash and equivalents has ranged from $14.19 million in 2017 to $264.55 million in 2024, and is currently $101.54 million as of their latest financial filing in 2025.

Over the last 9 years, Crinetics Pharmaceuticals' book value per share changed from 0.00 in 2016 to 10.45 in 2025, a change of 1,045.5%.

Related Companies

Financial statements for NASDAQ:CRNX last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crinetics Pharmaceuticals (CRNX) Financials

Financials Breakdown Chart

Key Financial Trends

Crinetics Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crinetics Pharmaceuticals (CRNX) Financials

Annual Income Statements for Crinetics Pharmaceuticals

Quarterly Income Statements for Crinetics Pharmaceuticals

Annual Cash Flow Statements for Crinetics Pharmaceuticals

Quarterly Cash Flow Statements for Crinetics Pharmaceuticals

Annual Balance Sheets for Crinetics Pharmaceuticals

Quarterly Balance Sheets for Crinetics Pharmaceuticals

Annual Metrics And Ratios for Crinetics Pharmaceuticals

Quarterly Metrics And Ratios for Crinetics Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Crinetics Pharmaceuticals Financials - Frequently Asked Questions

When does Crinetics Pharmaceuticals' financial year end?

How has Crinetics Pharmaceuticals' net income changed over the last 9 years?

What is Crinetics Pharmaceuticals' operating income?

How has Crinetics Pharmaceuticals' revenue changed over the last 9 years?

How much debt does Crinetics Pharmaceuticals have?

How much cash does Crinetics Pharmaceuticals have?

How has Crinetics Pharmaceuticals' book value per share changed over the last 9 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools